In this summary you will find clinical evidence on:

1. Clean Intermittent Self-Catheterisation
2. Urinary Tract Infections
3. Urethral Trauma
4. User evaluations

Download the full report (pdf, 3,976 KB)

1. Clean Intermittent Self-Catheterisation:

• Clean intermittent self-catheterization: a 12-year follow-up
• Clean intermittent catheterisation from the acute period in spinal cord injury patients. 
• Long-term evaluation of urethral and genital tolerance.
• Effect of bladder management on urological complications in 10 spinal cord injured patients.

2. Urinary Tract Infections:

• Hydrophilic versus non-coated catheters for intermittent catheterization. 
• Complications of intermittent catheterization: their prevention and treatment. 
• Intermittent catheterisation with hydrophilic-coated catheters (SpeediCath) reduces the risk of clinical urinary tract infection in spinal cord injured patients: a prospective randomised parallel comparative trial.
• Standard versus hydrophilic catheterization in the adjuvant treatment of patients with superficial bladder cancer.
• Intermittent catheterization with a hydrophilic-coated catheter delays the occurrence of urinary tract infection in patients with acute spinal cord injury: A prospective, randomized, parallel, multi-center trial.

3. Urethral Trauma:

• Complications of intermittent catheterization: their prevention and treatment.
• Urethral epithelial cells on the surface on hydrophilic catheters after intermittent catheterization: cross-over study with two catheters.
• Coated catheters for intermittent catheterization: smooth or sticky? 
• Hydrophilic-coated catheters for intermittent catheterisation reduce urethral micro trauma: a prospective, randomised, participant-blinded, crossover study of three different types of catheters.
• Safety of a new compact male intermittent catheter: a randomised, cross-over, single blind study in healthy male volunteers.
• Safety of a new compact catheter for men with neurogenic bladder dysfunction: a randomised, cross-over, open-labelled study.

4. User evaluations on:

• Pain & discomfort
• Ease of use

Download the full report (pdf, 3,976 KB)

In this monograph you can learn about:

1. Management of neurogenic bladder with urethral intermittent catheterisation
2. Intermittent catheterisation technique and long-term concordance
3. Key features of the SpeediCath family
4. The SpeediCath catheter range
5. Evidence from clinical studies of SpeediCath
6. Environment

Download the full report (pdf, 1 MB)

Many clinical studies and reviews have been published on transanal irrigation and the use of Peristeen. More than 1,000 patients have evaluated the treatment modality. Peristeen reduces symptoms of constipation and faecal incontinence. A large randomised controlled trial investigated the efficacy and safety of Peristeen compared to conservative bowel management treatment - defined as adjustment in diet and fluid, regular activity and use of laxatives or constipating medication(1).

Fig. 1: A significant reduction in constipation symptoms from 13.2 to 10.3 when using Peristeen compared to conservative treatment.

Fig. 2: A significant reduction in faecal incontinence symptoms from 7.3 to 5.0 when using Peristeen compared to conservative treatment.

Peristeen is proven to be safe in use

Fig. 3: Time spent on bowel management was reduced from 74.4 to 47.0 minutes when using Peristeen(2).

Fig. 4: List of side-effects when using Peristeen(3).

• Minor side effects were reported in 48% of patients in a long-term study
• One non-lethal bowel perforation occurred in ~ 50,000 irrigations

The Neurogenic Bowel Dysfunction (NBD) score is a recently developed, validated questionnaire to assess the impact of colorectal symptoms on patients’ quality of life(1).

The questionnaire could is also be useful to assess any change in the patient’s condition when tested 2–3 months after the initiation of colonic irrigation. This in turn could improve patient adherence to treatment.

This questionnaire is simple to use and can be self-administered by individual patients. It contains 10 questions; giving a total score of between 0 and 47, corresponding to the severity of colorectal disorders experienced. A score≥10 corresponds to moderate to severe bowel dysfunction and would justify the use of Peristeen.

We hope the NBD score will be a useful tool in your practice.

Download and print the questionnaire.